Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Bejon

Showing results (231-240 of 276) with videos related to

Pageof 28
Sort By:
Wellcome Open Research|August 25, 2025
Comparative performance of the InBios SCoV-2 Detect <sup>TM</sup> IgG ELISA and the in-house KWTRP ELISA in detecting SARS-CoV-2 spike IgG antibodies in Kenyan populationsBernadette Kutima, Eunice Wageci Kagucia, Kennedy Mwai, et al.
Plos One|December 3, 2010
Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian ChildrenJohn Lusingu, Ally Olotu, Amanda Leach, et al.
Lancet (London, England)|February 4, 2024
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trialMehreen S Datoo, Alassane Dicko, Halidou Tinto, et al.
Cell Reports|February 10, 2021
Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humansHenry J Sutton, Racheal Aye, Azza H Idris, et al.
Nature Communications|April 7, 2026
African-specific genetic loci determine iron status and risk of severe malaria and bacteremia in African childrenJohn Muthii Muriuki, Alexander J Mentzer, Gavin Band, et al.
Wellcome Open Research|May 6, 2024
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trialMainga Hamaluba, Samuel Sang, Benedict Orindi, et al.
The Journal of Infectious Diseases|October 23, 2014
Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individualsSusanne H Hodgson, Katie J Ewer, Carly M Bliss, et al.
Nature Communications|June 26, 2021
Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in KenyaIfedayo M O Adetifa, Sophie Uyoga, John N Gitonga, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 26, 2016
Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and InfantsMuhammed O Afolabi, Alfred B Tiono, Uche J Adetifa, et al.
Lancet (London, England)|May 10, 2026
Impact of introducing RTS,S/AS01<sub>E</sub> malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster-randomised implementation programmeVictor Mwapasa, Kwaku Poku Asante, Paul Milligan, et al.
Pageof 28

Showing results (231-240 of 276) with videos related to

Sort By:
Pageof 28
Wellcome Open Research|August 25, 2025
Comparative performance of the InBios SCoV-2 Detect <sup>TM</sup> IgG ELISA and the in-house KWTRP ELISA in detecting SARS-CoV-2 spike IgG antibodies in Kenyan populationsBernadette Kutima, Eunice Wageci Kagucia, Kennedy Mwai, et al.
Plos One|December 3, 2010
Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian ChildrenJohn Lusingu, Ally Olotu, Amanda Leach, et al.
Lancet (London, England)|February 4, 2024
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trialMehreen S Datoo, Alassane Dicko, Halidou Tinto, et al.
Cell Reports|February 10, 2021
Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humansHenry J Sutton, Racheal Aye, Azza H Idris, et al.
Nature Communications|April 7, 2026
African-specific genetic loci determine iron status and risk of severe malaria and bacteremia in African childrenJohn Muthii Muriuki, Alexander J Mentzer, Gavin Band, et al.
Wellcome Open Research|May 6, 2024
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trialMainga Hamaluba, Samuel Sang, Benedict Orindi, et al.
The Journal of Infectious Diseases|October 23, 2014
Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individualsSusanne H Hodgson, Katie J Ewer, Carly M Bliss, et al.
Nature Communications|June 26, 2021
Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in KenyaIfedayo M O Adetifa, Sophie Uyoga, John N Gitonga, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 26, 2016
Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and InfantsMuhammed O Afolabi, Alfred B Tiono, Uche J Adetifa, et al.
Lancet (London, England)|May 10, 2026
Impact of introducing RTS,S/AS01<sub>E</sub> malaria vaccine on mortality in young children in Ghana, Kenya, and Malawi: an observational evaluation of a cluster-randomised implementation programmeVictor Mwapasa, Kwaku Poku Asante, Paul Milligan, et al.
Pageof 28